Prevest Denpro Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Prevest Denpro Ltd trades at ₹425, in a downtrend and 15 weeks into that stage. That is −13.5% against its own 200-day average. It sits at 13% of a 52-week range of ₹401 to ₹586. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 3 straight weeks.

Today the stock is in a downtrend — week 15 of stage 4, confirmed. At ₹425 it trades −13.5% versus its 200-day average and sits at 13% of its 52-week range (₹401–₹586).

Against the market, two honest reads. Cumulative: over the last 4.4 years the stock moved +125% while the NIFTY 500 moved +49% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 3 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 15th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Prevest Denpro Ltd trades at 24.8× P/E, near the bottom of its own range — cheaper only 15% of the time. Its long-run median P/E is 32.5×, measured across 4.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 24.8× is near the bottom of its own range — cheaper only 15% of the time, against a long-run median of 32.5× measured over 4.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +12.9% against a −1.2% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 3y, of the +11.9%/yr price move, ~+16.4%/yr came from earnings growth and ~−4.5 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Prevest Denpro Ltd reads as improving on its fundamental arc. Improving — profit growth bottomed 6 quarters ago at −8.8% and has held its recovery at +15.5% (single-quarter readings), ROCE slipping at 25.0%. The read is built from 9 quarters across 3 curves, on partial evidence.

Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

71.7/100 — rank 1 of 6 in Medical Equipment · 73% evidence confidence

Prevest Denpro Ltd scores 71.7 out of 100 against the 6 companies it is compared with in Medical Equipment, ranking 1. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.

The four contributions add to the total exactly: 23.4 + 21.2 + 13.8 + 13.3 = 71.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Prevest Denpro Ltd reported ₹18.4 Cr of revenue in the Dec 25 quarter, +23.0% year on year. That is the 6th straight quarter of year-on-year growth. Over 6 years it has compounded at 22.1% a year. The last full year, FY25, came in at ₹63.0 Cr. The last four reported quarters add to ₹71.3 Cr.

Prevest Denpro Ltd reported ₹18.4 Cr of revenue in the Dec 25 quarter, +23.0% year on year. That is the 6th straight quarter of year-on-year growth. Over 6 years it has compounded at 22.1% a year. The last full year, FY25, came in at ₹63.0 Cr. The last four reported quarters add to ₹71.3 Cr.

FY25 revenue came in at ₹63.0 Cr (+12.5% on the year), capping 6 years at 22.1% compound. The latest quarter (Dec 25) printed ₹18.4 Cr, +23.0% year on year — the 6th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +17.4% growth against the decade's 22.1% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +17.3% over the last 4 quarters against +14.9%/yr over the last 8 — stabilising; TTM profit +17.0% vs +11.5%/yr — accelerating.

→ Revenue grew — did margins hold as it scaled? Next: 33.9% this quarter (−0.6 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Prevest Denpro Ltd's operating margin is 33.9% in the Dec 25 quarter, −0.6 percentage points against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 20.0% to 40.0%. The current quarter sits inside that band.

Prevest Denpro Ltd's operating margin is 33.9% in the Dec 25 quarter, −0.6 percentage points against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 20.0% to 40.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 33.9%, −0.6 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 20.0%–40.0%.

🚨 Why the margin moved: operating margin went −0.6 pp year on year while gross margin went +1.3 pp — the loss came mostly from the gross line: input costs and pricing.

→ Margins slipped — did that reach the bottom line? Next: profit +15.5% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Prevest Denpro Ltd earned ₹5.2 Cr of net profit in the Dec 25 quarter, +15.5% year on year. It is the 6th consecutive quarter of growth. Full-year FY25 profit was ₹18.0 Cr. The 6-year compound rate is 34.8%. That is 28.0% of the quarter's revenue. The same quarter a year earlier earned ₹4.5 Cr.

Prevest Denpro Ltd earned ₹5.2 Cr of net profit in the Dec 25 quarter, +15.5% year on year. It is the 6th consecutive quarter of growth. Full-year FY25 profit was ₹18.0 Cr. The 6-year compound rate is 34.8%. That is 28.0% of the quarter's revenue. The same quarter a year earlier earned ₹4.5 Cr.

Dec 25 profit was ₹5.2 Cr, +15.5% year on year — the 6th consecutive quarter of growth. On the full year, FY25 printed ₹18.0 Cr (+12.5%), and the 6-year compound rate is 34.8%.

Why profit moved: revenue contributed +23.0% and the margin −0.6 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +17.5% vs revenue +17.4%. Profit and revenue are moving roughly in step.

→ Profit rose — but did the cash follow? Next: 72% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 72% of Prevest Denpro Ltd's reported profit arrived as operating cash — most of the profit is real cash. In FY25 that was ₹15.0 Cr of operating cash against ₹18.0 Cr of profit. After ₹2.0 Cr of capital spending, ₹13.0 Cr was left as free cash.

FY25: operating cash of ₹15.0 Cr against reported profit of ₹18.0 Cr, leaving free cash of ₹13.0 Cr after ₹2.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 72% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 72%: the cash cycle stretched 189 days between FY20 and FY25 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: conversion is below par and the cash cycle has stretched 189 days — the next section's job is to find where the cash is stuck.

→ So follow the cash to where it goes. Next: the 211-day cycle, in money terms.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Prevest Denpro Ltd's cash conversion cycle runs 211 days in FY25, up from 22 days in FY20. Capital spending ran ₹19.0 Cr over the last 3 years. At FY25 sales of ₹63.0 Cr each day of that cycle holds about ₹0.2 Cr, so roughly ₹36.0 Cr sits inside the business at any moment.

FY25: debtors at 45 days, inventory at 208 days — roughly 6.8 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 211 days, looser than FY20's 22.

The full loop: cash goes out to suppliers and production on day 0; stock waits 208 days to sell; customers pay about 45 days after that; and suppliers themselves are paid at 42 days — netting out to the 211-day cycle.

In money terms: at FY25 sales of ₹63.0 Cr, each day of the cycle holds about ₹0.2 Cr — so the 211-day loop keeps roughly ₹36.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹19.0 Cr over the last 3 fiscal years against ₹4.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY25) — capacity paid for but not yet earning.

The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 25%.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Prevest Denpro Ltd earns a ROCE of 25% in FY25. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 28.6% net margin on 0.56× asset turns.

FY25 ROCE is 25%.

Why the return is what it is — the wiring (FY25): 28.6% net margin × 0.56× asset turns × 1.07× balance-sheet leverage ≈ 17.1% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.00.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Prevest Denpro Ltd carries ₹0.0 Cr of borrowings against ₹106 Cr of equity in FY25, a debt-to-equity of 0.00. Over 5 years borrowings went from ₹2.0 Cr to ₹0.0 Cr. Capital spending ran ₹19.0 Cr across the last 3 of those years.

FY25: borrowings of ₹0.0 Cr against equity of ₹106 Cr — a debt-to-equity of 0.00. Over 5 years borrowings went from ₹2.0 Cr to ₹0.0 Cr while capital spending ran ₹19.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.

→ Who owns this, and are they adding or leaving? Next: the register is quiet.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Prevest Denpro Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.1 points over the same window, to 0.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: +0.3 points over 8 quarters to 0.7%; Domestic institutions: +0.1 points over 8 quarters to 0.8%; Promoters: +0.0 points over 8 quarters to 73.6%.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Prevest Denpro Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions